An epitope is the specific part of an antigen that an antibody recognizes and binds. Defining that site — rather than only knowing that binding occurs — turns an antibody from a black box into a characterized reagent. Epitope mapping answers where on the antigen the antibody lands, what kind of structure it engages, and how that information can be used in assay design, engineering, or competition studies.
Epitopes fall into two broad classes. A linear epitope is a short continuous stretch of the sequence, typically around 5 to 20 amino acids, that survives denaturing conditions such as those used in a Western blot, where the antibody can still recognize a precise peptide fragment. A conformational epitope is formed by residues brought together only when the protein is folded, so it depends on three-dimensional structure rather than a single local sequence. Mapping one class versus the other calls for different tools, which is why a mapping program is usually built around more than one method.
Figure 1. Epitope mapping via DMS applications. (Source: Keen MM, et al. 2025)
The choice of method depends on the epitope type, the sample available, and how precise the localization must be. The approaches below are applied singly or in combination so that both linear and conformational sites are addressed.
Peptide library screening. Overlapping synthetic peptides that walk along the antigen sequence are screened against the antibody. Where the antibody binds a peptide, a linear epitope is identified at residue resolution. This approach is direct, tolerant of modest sample amounts, and particularly effective for epitopes that survive denaturation.
LC-MS / mass spectrometry. The antigen is digested and the peptide fraction bound by the antibody is isolated and identified by mass spectrometry. The recovered peptide identities point to the antigen region the antibody engages, providing residue-level evidence without requiring the antigen to remain folded.
3D electron microscopy. When an antigen–antibody complex can be prepared, three-dimensional electron microscopy localizes the binding region on the intact complex. This route needs only a small amount of antigen or complex and can be completed on a compressed timeline, making it practical when material is limited.
X-ray crystallography. Obtaining a co-crystal of the antigen and antibody, then solving the structure, gives the most detailed view of the interacting surfaces. The barrier is practical: it requires high-purity antigen and antibody and the establishment of crystallization conditions, and it is not always feasible when the target protein is scarce. Where crystallization succeeds, however, it resolves both linear and conformational contacts at atomic detail.
Computational prediction. Sequence- and structure-based algorithms estimate epitope regions from properties such as hydrophilicity, accessibility, and flexibility. Because it runs in silico, this route is fast and low-cost and is commonly used to narrow candidates before laboratory work. Since no single algorithm is exact, a panel of complementary prediction tools is applied and the agreement across them is used to report the most consistent regions.
| Method | What it best resolves | Sample need | Notes |
| Peptide library screening | Linear epitopes | Modest | Residue-level; works under denaturing conditions |
| LC-MS | Bound peptide region | Modest | Residue-level without folding requirement |
| 3D electron microscopy | Epitope on intact complex | Small | Compressed timeline; structure-dependent sites |
| X-ray crystallography | Full interaction surface | High purity, abundant | Atomic detail; crystallization can be limiting |
| Computational prediction | Candidate regions | Sequence/structure only | Fast, low-cost; best as a pre-experimental filter |
Reference